Evidence map›Paper›PMID 31931831›Full record

ArticleSubstance abuse treatment, prevention, and policy2020

A rapid access to addiction medicine clinic facilitates treatment of substance use disorder and reduces substance use.

David Wiercigroch, Hasan Sheikh, Jennifer Hulme

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Substance abuse treatment, prevention, and policy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05594121 (A Pragmatic, Multi-centre, Open-label, Randomized, 12-month, Parallel Group, Superiority Study to Compare the Effectiveness of Subcutaneous Buprenorphine Depot), which is not on this map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
6.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05594121 phase4unknown statusnot on this mapstarted 2022, after this paper: background citation

A Pragmatic, Multi-centre, Open-label, Randomized, 12-month, Parallel Group, Superiority Study to Compare the Effectiveness of Subcutaneous Buprenorphine Depot (Sublocade®) vs Daily Sublingual Buprenorphine With Naloxone (Suboxone®) for the Treatment of Opioid Use Disorder

TypeinterventionalSponsorRoyal Victoria Hospital, CanadaRan2022 to 2024Enrolled90ConditionsModerate to Severe Opioid Use DisorderArmsExtended Release Subcutaneous Buprenorphine, Immediate Release Sublingual Buprenorphine
3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 54 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Training in Substance use Disorders, Part 1: Overview of Clinical Practice Recommendations.Canadian journal of psychiatry. Revue canadienne de psychiatrie · 2024
    Article
  10. Article
  11. Article
  12. Article
  13. Observational
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

David WiercigrochFaculty of Medicine, University of Toronto, 1 King's College Cir, Toronto, Ontario, M5S 1A8, Canada. d.wiercigroch@mail.utoronto.ca.ORCID 0000-0003-4135-3550
Hasan SheikhDepartment of Family and Community Medicine, University of Toronto, 500 University Avenue, 5th Floor, Toronto, Ontario, M5G 1V7, Canada.
Jennifer HulmeDepartment of Family and Community Medicine, University of Toronto, 500 University Avenue, 5th Floor, Toronto, Ontario, M5G 1V7, Canada.
University Health Network · CAUniversity of New Brunswick · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSubstance use is prevalent in Canada, yet treatment is inaccessible. The Rapid Access to Addiction Medicine (RAAM) clinic opened at the University Health Network (UHN) in January 2018 as part of a larger network of addictions clinics in Toronto, Ontario, to enable timely, low barrier access to medical treatment for substance use disorder (SUD). Patients attend on a walk-in basis without requiring an appointment or referral. We describe the RAAM clinic model, including referral patterns, patient demographics and substance use patterns. Secondary outcomes include retention in treatment and changes in both self-reported and objective substance use.

methodsThe Electronic Medical Record at the clinic was reviewed for the first 26 weeks of the clinic's operation. We identified SUD diagnoses, referral source, medications prescribed, retention in care and self-reported substance use.

resultsThe clinic saw 64 unique patients: 66% had alcohol use disorder (AUD), 39% had opiate use disorder (OUD) and 20% had stimulant use disorder. Fifty-five percent of patients were referred from primary care providers, 30% from the emergency department and 11% from withdrawal management services. Forty-two percent remained on-going patients, 23% were discharged to other care and 34% were lost to follow-up. Gabapentin (39%), naltrexone (39%), and acamprosate (15%) were most frequently prescribed for AUD. Patients with AUD reported a significant decrease in alcohol consumption at their most recent visit. Most patients (65%) with OUD were prescribed buprenorphine, and most patients with OUD (65%) had a negative urine screen at their most recent visit.

conclusionThe RAAM model provides low-barrier, accessible outpatient care for patients with substance use disorder and facilitates the prescription of evidence-based pharmacotherapy for AUD and OUD. Patients referred by their primary care physician and the emergency department demonstrated a reduction in median alcohol consumption and high rates of opioid abstinence.

Indexed as

AcamprosateAddiction MedicineAdultAgedAlcohol DeterrentsAlcoholismBuprenorphineEmergency Service, HospitalFemaleGabapentinHumansMaleMiddle AgedNaltrexoneOntarioOpioid-Related DisordersAcamprosateAlcohol DeterrentsBuprenorphineGabapentinNaltrexoneAddictionalcoholBuprenorphineLow-barrierOpioidOutpatientRAAMsubstance use

Identifiers

PMID31931831
PMCPMC6958640
OpenAlexW2999746377

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.